The venetoclax-based regimen was associated with an approximate $8000 decrease in costs compared with the continuous Bruton ...

NORTH CHICAGO, Ill. and BOSTON, Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...

Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

AbbVie is strengthening its neurology portfolio with a $1.4 billion acquisition of Aliada Therapeutics. The North Chicago-based drugmaker said in a statement this morning that Aliada has a blood ...

AbbVie aims to best those drugs through its acquisition of Aliada Therapeutics, a biotech whose technology enables large molecules such as antibodies to cross this protective barrier. AbbVie ...

AbbVie has made a big move in the Alzheimer’s space just a few months after it dropped its own internal candidate over the summer. On Monday, the pharma company announced a $1.4 billion acquisition of ...

Are you a print subscriber? Activate your account. By Adrianne Pasquarelli - 2 hours 3 min ago By Erika Wheless - 2 hours 3 min ago By Brian Bonilla - 2 hours 3 min ago By Tim Nudd - 2 hours 3 min ...

Imbruvica is an important drug for AbbVie and is its biggest revenue producer ... because they have historically responded poorly to ibrutinib therapy. Despite the failure to meet the overall ...

In the last three months, 11 analysts have published ratings on AbbVie (NYSE:ABBV), offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their ...